James C. Felli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
James C. Felli has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Derek J. Leishman
Department of Drug Disposition, Toxicology and PKPD, Eli Lilly and Company, Indianapolis, IN 46285, United States of America
1 shared publication- Derek J. Leishman
Eli Lilly and Company, Indianapolis, USA
1 shared publication Patrizia A. Cavazzoni
Eli Lilly & Company, Indianapolis, IN
1 shared publicationRebecca A. Noel
Eli Lilly & Company, Indianapolis, IN
1 shared publication
Latest Publications
- 1 September 2020
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 105, 106898
A Bayesian approach to toxicological testing
- 1 September 2020
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 105, 106898
A Bayesian approach to toxicological testing
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106603
Real estate diagrams: A tool to quickly assess the utility of a new predictive technology
- 1 September 2019
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 99, 106603
Real estate diagrams: A tool to quickly assess the utility of a new predictive technology
- 1 January 2009
- Published by SAGE Publications in Medical Decision Making
- Vol. 29 (1) , 104-115
A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives
The assessment of the benefits and risks associated with a medicine's use requires careful consideration of a wealth of information of varying format and quality, ranging from efficacy and safety data derived from randomized clinical trials to statistical results from health outcomes studies to spontaneously reported adverse events. Contrary to the expectations of patients, physicians, and regulators, the literature offers little guidance as to how to strike an appropriate balance between benefit and risk. Although a qualitative listing of a medicine's benefits and risks is useful, much could be gained from a systematic and transparent process to evaluate a medicine's pre- and postmarketing performance. The authors propose a representational model based on multicriteria decision analysis that can incorporate both evaluative judgments from different perspectives (e.g., physician, patient) and quantitative data to inform tradeoffs between multiple benefit and multiple risk elements in a logically consistent and transparent manner. The model is designed to highlight the relative merits and deficits of treatment alternatives in well-defined and specific contexts. It is intended to serve as a common platform to facilitate focused benefit-risk tradeoff discussions between scientists, physicians, regulatory authorities, and pharmaceutical companies, and to assist in the communication of clear and consistent messages regarding those tradeoffs.
- 1 January 2009
- Published by SAGE Publications in Medical Decision Making
- Vol. 29 (1) , 104-115
A Multiattribute Model for Evaluating the Benefit-Risk Profiles of Treatment Alternatives
The assessment of the benefits and risks associated with a medicine's use requires careful consideration of a wealth of information of varying format and quality, ranging from efficacy and safety data derived from randomized clinical trials to statistical results from health outcomes studies to spontaneously reported adverse events. Contrary to the expectations of patients, physicians, and regulators, the literature offers little guidance as to how to strike an appropriate balance between benefit and risk. Although a qualitative listing of a medicine's benefits and risks is useful, much could be gained from a systematic and transparent process to evaluate a medicine's pre- and postmarketing performance. The authors propose a representational model based on multicriteria decision analysis that can incorporate both evaluative judgments from different perspectives (e.g., physician, patient) and quantitative data to inform tradeoffs between multiple benefit and multiple risk elements in a logically consistent and transparent manner. The model is designed to highlight the relative merits and deficits of treatment alternatives in well-defined and specific contexts. It is intended to serve as a common platform to facilitate focused benefit-risk tradeoff discussions between scientists, physicians, regulatory authorities, and pharmaceutical companies, and to assist in the communication of clear and consistent messages regarding those tradeoffs.